Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer

Authors: Olga Prokopchuk, Barbara Grünwald, Ulrich Nitsche, Carsten Jäger, Oleksii L. Prokopchuk, Elaine C. Schubert, Helmut Friess, Marc E. Martignoni, Achim Krüger

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Tissue inhibitor of metalloproteinases-1 (TIMP-1) is a candidate diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma (PDAC). Here, we determined the possible association of systemic TIMP-1 levels with cachexia and jaundice, two common PDAC-associated conditions.

Methods

Plasma TIMP-1 was measured by ELISA in patients diagnosed with PDAC (n = 36) and chronic pancreatitis (CP) (n = 25). Patients without pancreatic pathologies and known malignancies of other origin served as controls (n = 13). TIMP-1 levels in these patients were tested for asscociation with jaundice and chachexia, and furthermore correlated with cachexia-related clinical parameters such as weight loss and ferritin, parameters of lung function, hemoglobin and liver synthesis parameters.

Results

TIMP-1 plasma levels were mostly higher in CP and PDAC patients with concomitant jaundice or cachexia. Elevated plasma TIMP-1 levels were also associated with clinical cachexia markers, including absolute and relative values of weight loss and lung function, as well as ferritin, hemoglobin, and cholinesterase levels. TIMP-1 levels significantly correlated with cachexia only in patients without jaundice. Jaundice also impaired the use of TIMP-1 as a prognostic marker in cancer patients. Relating to cachexia status alone, a slightly improved association of TIMP-1 levels with survival of PDAC patients was observed.

Conclusion

This retrospective study reports for the first time that plasma levels of TIMP-1 are associated with pancreatic lesion-induced cachexia in patients without jaundice. TIMP-1 is counterindicated as a survival marker in patients with jaundice.
Literature
1.
Seubert B, Grunwald B, Kobuch J, Cui H, Schelter F, Schaten S, et al. Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice. Hepatology. 2015;61(1):238–48.CrossRefPubMed
2.
Holten-Andersen MN, Stephens RW, Nielsen HJ, Murphy G, Christensen IJ, Stetler-Stevenson W, et al. High preoperative plasma tissue inhibitor of metalloproteinase-1 levels are associated with short survival of patients with colorectal cancer. Clin Cancer Res. 2000;6:4292–9.PubMed
3.
Wurtz SO, Moller S, Mouridsen H, Hertel PB, Friis E, Brunner N. Plasma and serum levels of tissue inhibitor of metalloproteinases-1 are associated with prognosis in node-negative breast cancer: a prospective study. Mol Cell Proteomics. 2008;7:424–30.CrossRefPubMed
4.
Kozlowski M, Laudanski W, Mroczko B, Szmitkowski M, Milewski R, Lapuc G. Serum tissue inhibitor of metalloproteinase 1 (TIMP-1) and vascular endothelial growth factor a (VEGF-A) are associated with prognosis in esophageal cancer patients. Adv Med Sci. 2013;58:227–34.CrossRefPubMed
5.
Cheng G, Fan X, Hao M, Wang J, Zhou X, Sun X. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer. Mol Cancer. 2016;15:30.CrossRefPubMedPubMedCentral
6.
Song G, Xu S, Zhang H, Wang Y, Xiao C, Jiang T, et al. TIMP1 is a prognostic marker for the progression and metastasis of colon cancer through FAK-PI3K/AKT and MAPK pathway. J Exp Clin Cancer Res. 2016;35:148.CrossRefPubMedPubMedCentral
7.
Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res. 1995;1:899–906.PubMed
8.
Alpizar-Alpizar W, Laerum OD, Christensen IJ, Ovrebo K, Skarstein A, Hoyer-Hansen G, et al. Tissue inhibitor of Metalloproteinase-1 is confined to tumor-associated Myofibroblasts and is increased with progression in gastric adenocarcinoma. J Histochem Cytochem. 2016;64:483–94.CrossRefPubMedPubMedCentral
9.
Yoshikawa T, Cho H, Tsuburaya A, Kobayashi O. Impact of plasma tissue inhibitor of metalloproteinase-1 on long-term survival in patients with gastric cancer. Gastric Cancer. 2009;12:31–6.CrossRefPubMed
10.
An HJ, Lee YJ, Hong SA, Kim JO, Lee KY, Kim YK, et al. The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer. Pathol Res Pract. 2016;212:357–64.CrossRefPubMed
11.
Cui H, Seubert B, Stahl E, Dietz H, Reuning U, Moreno-Leon L, et al. Tissue inhibitor of metalloproteinases-1 induces a pro-tumourigenic increase of miR-210 in lung adenocarcinoma cells and their exosomes. Oncogene. 2015;34:3640–50.CrossRefPubMed
12.
Cui H, Grosso S, Schelter F, Mari B, Kruger A. On the pro-metastatic stress response to cancer therapies: evidence for a positive co-operation between TIMP-1, HIF-1alpha, and miR-210. Front Pharmacol. 2012;3:134.CrossRefPubMedPubMedCentral
13.
Kruger A. Premetastatic niche formation in the liver: emerging mechanisms and mouse models. J Mol Med (Berl). 2015;93:1193–201.CrossRef
14.
Grunwald B, Harant V, Schaten S, Fruhschutz M, Spallek R, Hochst B, et al. Pancreatic pre-malignant lesions secrete TIMP1, which activates hepatic stellate cells via CD63 signaling to create a pre-metastatic niche in the liver. Gastroenterology. 2016;151(5):1011-24.
15.
Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, Groblewska M, Gryko M, Kedra B, et al. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas. 2009;38:613–8.CrossRefPubMed
16.
Poruk KE, Firpo MA, Scaife CL, Adler DG, Emerson LL, Boucher KM, et al. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Pancreas. 2013;42:193–7.CrossRefPubMedPubMedCentral
17.
Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Buchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer. 1995;62:407–13.CrossRefPubMed
18.
Gong YL, Xu GM, Huang WD, Chen LB. Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancer. J Surg Oncol. 2000;73:95–9.CrossRefPubMed
19.
Zhang H, Liu B, Xu XF, Jiang TT, Zhang XQ, Shi YL, et al. Pathophysiology of chronic pancreatitis induced by dibutyltin dichloride joint ethanol in mice. World J Gastroenterol. 2016;22:2960–70.CrossRefPubMedPubMedCentral
20.
Pan S, Chen R, Crispin DA, May D, Stevens T, McIntosh MW, et al. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. J Proteome Res. 2011;10:2359–76.CrossRefPubMedPubMedCentral
21.
Pan S, Chen R, Brand RE, Hawley S, Tamura Y, Gafken PR, et al. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res. 2012;11:1937–48.CrossRefPubMedPubMedCentral
22.
Jenkinson C, Elliott V, Menon U, Apostolidou S, Fourkala OE, Gentry-Maharaj A, et al. Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. J Proteome. 2015;113:400–2.CrossRef
23.
Bachmann J, Buchler MW, Friess H, Martignoni ME. Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Nutr Cancer. 2013;65:827–33.CrossRefPubMed
24.
Springer J, Tschirner A, Haghikia A, von Haehling S, Lal H, Grzesiak A, et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J. 2014;35:932–41.CrossRefPubMed
25.
Toneto AT, Ferreira Ramos LA, Salomao EM, Tomasin R, Aereas MA, Gomes-Marcondes MC. Nutritional leucine supplementation attenuates cardiac failure in tumour-bearing cachectic animals. J Cachexia Sarcopenia Muscle. 2016;7(5):577-86.
26.
Devine RD, Bicer S, Reiser PJ, Velten M, Wold LE. Metalloproteinase expression is altered in cardiac and skeletal muscle in cancer cachexia. Am J Physiol Heart Circ Physiol. 2015;309:H685–91.CrossRefPubMedPubMedCentral
27.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.CrossRefPubMed
28.
Martignoni ME, Dimitriu C, Bachmann J, Krakowski-Rosen H, Ketterer K, Kinscherf R, et al. Liver macrophages contribute to pancreatic cancer-related cachexia. Oncol Rep. 2009;21:363–9.PubMed
29.
Skorokhod A, Bachmann J, Giese N, Martignoni ME, Krakowski-Roosen H. Real-imaging cDNA-AFLP transcript profiling of pancreatic cancer patients: Egr-1 as a potential key regulator of muscle cachexia. BMC Cancer. 2012;12:265.CrossRefPubMedPubMedCentral
30.
Schwarz S, Prokopchuk O, Esefeld K, Groschel S, Bachmann J, Lorenzen S, et al. The clinical picture of cachexia: a mosaic of different parameters (experience of 503 patients). BMC Cancer. 2017;17:130.CrossRefPubMedPubMedCentral
31.
Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Buchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg. 2008;12:1193–201.CrossRefPubMed
32.
Bachmann J, Ketterer K, Marsch C, Fechtner K, Krakowski-Roosen H, Buchler MW, et al. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer. 2009;9:255.CrossRefPubMedPubMedCentral
33.
Prokopchuk O, Steinacker J, Nitsche U, Otto S, Bachmann J, Schubert E, et al. IL-4 mRNA is downregulated in the liver of pancreatic cancer patients suffering from cachexia. Nutr Cancer. 2016;69 in press
34.
35.
Cascinu S, Falconi M, Valentini V, Jelic S, Group EGW. Pancreatic Cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(Suppl 5):v55–8.CrossRefPubMed
36.
37.
Argiles JM, Lopez-Soriano FJ, Toledo M, Betancourt A, Serpe R, Busquets S. The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J Cachexia Sarcopenia Muscle. 2011;2:87–93.CrossRefPubMedPubMedCentral
38.
Joergensen MT, Brunner N, De Muckadell OB. Comparison of circulating MMP-9, TIMP-1 and CA19-9 in the detection of pancreatic cancer. Anticancer Res. 2010;30:587–92.PubMed
39.
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266–70.CrossRefPubMed
40.
Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol. 2000;26:474–9.CrossRefPubMed
Metadata
Title
Elevated systemic levels of the matrix metalloproteinase inhibitor TIMP-1 correlate with clinical markers of cachexia in patients with chronic pancreatitis and pancreatic cancer
Authors
Olga Prokopchuk
Barbara Grünwald
Ulrich Nitsche
Carsten Jäger
Oleksii L. Prokopchuk
Elaine C. Schubert
Helmut Friess
Marc E. Martignoni
Achim Krüger
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4055-9

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Prognostic nutritional index as a predictor of survival in resectable gastric cancer patients with normal preoperative serum carcinoembryonic antigen levels: a propensity score matching analysis

Correction

Correction to: Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens

Research article

Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancer

Research article

Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality

Research article

Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer

Research article

LGR5 overexpression confers poor relapse-free survival in breast cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits